Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Cancer Treatment
100%
Meta-Analysis
82%
Prostate Cancer
82%
Malignant Neoplasm
82%
Radiation Therapy
77%
Clinical Trial
57%
Arm
54%
Diseases
47%
Clinical Research
42%
Androgen Deprivation Therapy
36%
Progression Free Survival
36%
Overall Survival
34%
Cohort Analysis
34%
Hazard Ratio
32%
Hodgkin's Lymphoma
32%
Pooled Analysis
32%
Soft Tissue Sarcoma
32%
Childhood Cancer
32%
Osteosarcoma
32%
Adolescence
27%
Malnutrition
25%
Radiation Dose Escalation
22%
Prostate Specific Antigen
21%
Phase II Trials
20%
Survival Rate
20%
Chemotherapy
20%
Patient-Data
20%
Diagnostic Test
19%
Symptomatic Treatment
18%
External Beam Radiotherapy
18%
Leiomyosarcoma
18%
Treatment Modality
18%
Prevalence
18%
Long-Term Outcome
17%
Edema
17%
Distant Metastasis
17%
Cancer Registry
16%
Neoplasm
16%
Doxorubicin
16%
Vinblastine
16%
Bleomycin
16%
Adriamycin Bleomycin Vinblastine Dacarbazine
16%
Polyethylene Terephthalate
16%
Acute Kidney Injury
16%
Clinical Trial Design
16%
Metastatic Kidney Cancer
16%
Sunitinib
16%
Nephrectomy
16%
Androgen Suppression
16%
Plasma Cell Granuloma
16%
Keyphrases
European Organizations
36%
Cancer Treatment
36%
Limited-stage
32%
Belgium
32%
Hodgkin Lymphoma
32%
Radiotherapy
24%
5-flucytosine
24%
Prostate Cancer
23%
Relapse Risk
19%
Linked Databases
18%
Hazard Ratio
18%
Radiotherapy Dose
17%
Localized Prostate Cancer
16%
External Beam Radiotherapy
16%
Treatment Intensification
16%
Sustained Release Pellets
16%
Severe Malnutrition
16%
Eastern Democratic Republic of Congo
16%
Dacarbazine
16%
Maximum Tumor Diameter
16%
Relapse Pattern
16%
Meta-analysis
16%
Trial Participants
16%
Metastasis-free Survival
16%
Failure Event
16%
Bleomycin
16%
EORTC
16%
Androgen Deprivation Therapy
16%
Type AB Thymoma
16%
Microfilaremia
16%
Vinblastine
16%
Cryptococcal Meningitis
16%
Pellet Formulation
16%
Combined Modality Therapy
16%
Dynamic Patterns
16%
Clinical Research Tools
16%
Adolescents Living with HIV (ALHIV)
16%
Dynamic Predictors
16%
Antiretroviral Adherence
16%
Cohort Follow-up
16%
Metastatic Kidney Cancer
16%
Hospitalization
16%
Netherlands Cancer Registry
16%
Sample Size Computation
16%
Palliative Cancer Care
16%
Doxorubicin
16%
Arm Weight
16%
Antiepileptic Drugs
16%
Intermediate Risk
16%
Androgen Suppression
16%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
86%
Prostate Cancer
65%
Androgen
36%
Sustained Release
32%
Flucytosine
32%
Bioavailability
32%
Overall Survival
30%
Prevalence
29%
Diseases
22%
Prostate Specific Antigen
21%
Progression Free Survival
21%
Tablet
18%
Cohort Study
17%
Distant Metastasis
17%
Cancer Registry
16%
Osteosarcoma
16%
Soft Tissue Sarcoma
16%
Normal Human
16%
Crizotinib
16%
Plasma Cell Granuloma
16%
Hepatitis B
16%
Stillbirth
16%
Synovial Sarcoma
16%
Liposarcoma
16%
Cryptococcal Meningitis
16%
Anaplastic Lymphoma Kinase
16%
Clinical Trial Design
16%
Acute Kidney Failure
16%
Anticonvulsive Agent
16%
Vaccination
16%
Malnutrition
16%
Congenital Malformation
16%
Psychotropic Agent
16%
Breast Cancer
10%
Distant Metastasis Free Survival
10%
Pharmacokinetics
9%
Survival Rate
9%
Sodium Valproate
8%
Disease Free Survival
7%
HIV
7%
Meningoencephalitis
6%
Antidepressant
5%
